Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- PMID: 33271289
- DOI: 10.1016/j.annonc.2020.11.016
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Conflict of interest statement
Disclosure TP reports research funding from Merck Serono, Merck Sharp & Dohme, Roche, BMS, Astra Zeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelexis and Eisai, and honararia from Merck Serono, Merck Sharp & Dohme, Roche, BMS, Astra Zeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelexis and Eisai.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
